Improved analogs and novel delivery systems for somatostatin octapeptides

J. P. Moreau, S. Kim, J. Z. Dong, F. Ignatious, S. Jackson, S. C. Moreau, B. A. Morgan, F. Touraud, J. E. Taylor, B. Tissier, M. Pellet, W. Murphy, T. Davis

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Appropriate N-terminus modification can result in somatostatin (SRIF) octapeptide analogs that are both more potent and more selective in vitro for the human SRIF receptor type 2 (hsst2). In addition, these modifications can improve the duration of action and bioavailability of SRIF analogs following parenteral administration, as shown by both pharmacological and distribution studies in vivo with BIM-23190 and BIM-23197 in the rat.

Original languageEnglish (US)
Pages (from-to)24-26
Number of pages3
JournalMetabolism: Clinical and Experimental
Issue numberSUPPL.1
StatePublished - 1996

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Improved analogs and novel delivery systems for somatostatin octapeptides'. Together they form a unique fingerprint.

Cite this